tyrvaya
·Code: OC-01
tyrvaya: developed by 2 companies · 1 FDA decision. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Oyster Point Pharma, Inc. (OYST) | Approved |
| Viatris Inc (VTRS) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )(OYST)
Frequently asked questions
Who is developing tyrvaya?
tyrvaya is being developed by Oyster Point Pharma, Inc., Viatris Inc.
What is tyrvaya's latest FDA decision?
The most recent tracked FDA decision for tyrvaya is Approval for 1 INDICATIONS AND USAGE TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 ), dated October 15, 2021.
Get deeper analysis on tyrvaya
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis